Glassia: Phase II started

Kamada and Baxalta began an open-label, Israeli Phase II trial to compare IV Glassia plus the standard of care (SOC) vs. SOC alone in 30 lung transplant recipients. Patients will receive Glassia every other day for 14 days, then once every 2 weeks until week 8, followed by monthly treatment thereafter. SOC includes systemic corticosteroids and immunosuppressants. ...